CSR Program: Jhpiego | Takeda Pharmaceuticals

India accounts for 17% of global maternal deaths and 26% of global neonatal deaths. Delays in reaching and receiving care, inadequate provider competency, poor care quality, limited data availability and fragmented systemic support contribute to adverse effects for women and newborns. The program will decentralize care to promote coordinated, patient-centered approaches for antenatal through to postnatal care; develop a digital tracking platform for pregnant women; and enable early identification of high-risk pregnancies by leveraging predictive analytics. The program aims to provide targeted care to women and encourage informed decision-making.